GlassScriptPhysician profile
Joy Iskandar
NPI 1841685724
$2,525.20
in general payments reported to CMS, 2019-2025
15 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $365 · 2021: $84.64 · 2022: $196 · 2023: $475 · 2024: $567 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.66 |
| Education | $239.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $672.13 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $655.13 | 2020-2025 | |
| Amgen INC. | $257.35 | 2023-2025 | Krystexxa, Tavneos, Otezla |
| E.R. Squibb & Sons, L.L.C. | $189.88 | 2019-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $177.51 | 2019-2021 | |
| Pfizer INC. | $143.83 | 2023-2025 | |
| Glaxosmithkline, LLC. | $109.87 | 2019-2020 | |
| Genentech USA, INC. | $99.99 | 2020 | |
| Lilly USA, LLC | $71.99 | 2019-2021 | |
| Novo Nordisk INC | $38.01 | 2023 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $28.29 | 2024 | Cologuard Collection Kit |
| Genzyme Corporation | $22.49 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.49 | 2025 | |
| Horizon Therapeutics Plc | $21.79 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.45 | 2025 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Iskandar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.